The Real Eisman Playbook

A new deal allowing NVIDIA (NVDA) and AMD (AMD) to sell AI chips to China presents a significant revenue opportunity, with NVDA's August 27th earnings being a key catalyst to watch. An expected resurgence in M&A activity is a bullish catalyst for investment banks, making firms like Goldman Sachs (GS) and pure-play advisor PJT Partners (PJT) attractive investments. Investors should favor companies with strong growth narratives like T-Mobile (TMUS), which is taking market share, over apparent value traps such as Verizon (VZ) and AT&T (T). Conversely, stocks like UnitedHealth (UNH) face significant fundamental problems and slashed guidance, warranting caution. The consulting firm Gartner (IT) is also a stock to avoid due to the existential threat AI poses to its business model.

Maintain a long-term bullish outlook on the U.S. market, focusing on domestic growth stories in technology and industrials. The Artificial Intelligence (AI) theme is a primary opportunity, driving growth in tech leaders like Amazon (AMZN) and Google (GOOGL). A potential U.S. manufacturing renaissance, spurred by significant tax incentives, presents a strong investment case for the industrial sector. The main risk to monitor is a potential U.S.-China trade war, which could disrupt the global economy. Investors should look past short-term negative data, as it is likely temporary noise from trade disputes.

Arista Networks (ANET) stands out as a key beneficiary of the AI boom, with strong earnings and a commitment to double-digit growth beyond 2025. Conversely, investors should be cautious of tech consulting firms like Gartner (IT), as AI may be cannibalizing its revenue. Shopify (SHOP) also presents a compelling growth story, forecasting revenue growth in the mid-to-high 20s percentage range. Due to tariff advantages, consider companies with significant manufacturing in Canada and Mexico as they hold a competitive edge. Finally, avoid "meme stocks" with deteriorating fundamentals like Open Door (OPEN), which guided revenue to be nearly cut in half.

Focus on the Artificial Intelligence theme by investing in public companies that apply AI to their specific industries using proprietary data, rather than the large model creators. Consider exposure to the cryptocurrency space, as sophisticated investors view blockchain as a foundational technology for the future of finance. Ripple (XRP) is highlighted as a key holding by successful early venture investors in the sector. Keep an eye on the emerging trend of tokenization, which involves representing real-world assets as digital tokens on a blockchain. For regulated access to this asset class, look to institutional products from firms like Grayscale.

Microsoft (MSFT) and Meta Platforms (META) are demonstrating exceptional growth driven by their successful AI strategies, making them high-conviction buys. To capitalize on a potential M&A wave, consider advisory firms like PJT Partners (PJT), which benefit from increased deal-making activity. S&P Global (SPGI) also presents a strong opportunity, leveraging its duopoly power to deliver strong earnings and raise future guidance. Conversely, investors should avoid UnitedHealth (UNH) as it faces severe fundamental challenges, regulatory investigations, and has not yet found a bottom. Lastly, PayPal (PYPL) and Novo Nordisk (NVO) are also unattractive due to slowing growth and intense competitive pressures.

Consider shorting pet-related stocks like Fresh Pet (FRPT) and Trupanion (TRUP), as both face slowing growth and fundamentally flawed business models. Specialty insurer Kinsale Capital (KNSL) is another potential short due to its extreme valuation of ~7 times book value and risks from a softening insurance market. For a longer-term bearish view, consider Shutterstock (SSTK), whose stock image business is directly threatened by the rise of AI image generation. The entire title insurance sector is also presented as a structural short, as real estate brokerages are destroying its business model by bundling the service. Finally, secular trends away from junk food, accelerated by GLP-1 drugs, create a bearish case for companies like Pepsi (PEP).